Results From Fully Enrolled NEURO-TTRansform Trial Due Mid-2022

Results From Fully Enrolled NEURO-TTRansform Trial Due Mid-2022

301586

Results From Fully Enrolled NEURO-TTRansform Trial Due Mid-2022

Patient enrollment is complete for the Phase 3 NEURO-TTRansform trial testing Ionis Pharmaceuticals’ eplontersen in adults with familial amyloid polyneuropathy (FAP). The trial exceeded its enrollment target of 140 participants, with Ionis now expecting to register more than 160 patients in the study. “The speed of enrollment in our pivotal NEURO-TTRansform study speaks to the urgent need for new treatment options for people living with [hereditary transthyretin (ATTR) amyloidosis],” Brett P. Monia, PhD, Ionis’ CEO, said…

You must be logged in to read/download the full post.